title: High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk.
abstract: BRCA1 mutation carriers have up to 80% life-time risk of developing breast cancer and 20-40% risk of developing ovarian cancer. High LH levels have been linked to increased risks of both breast and ovarian cancers in some studies and it is unknown whether gonadotropin levels are associated with BRCA1 mutation status. The aim of the study was to explore whether gonadotropin levels were associated with BRCA1 mutation status among healthy 40-year-old-women from hereditary breast cancer families. All women completed a questionnaire including information on reproductive factors and OC use. We measured height, weight, breast volumes, and plasma levels of LH, FSH, and estradiol (E2) once during menstrual cycle days 5-10 and once again during cycle days 18-23 in 43 non-carriers from BRCA1 families, 20 BRCA1 mutation carriers, and 101 women from non-BRCA1/2 families. The strongest predictors of high LH levels among BRCA1 mutation carriers and non-carriers during cycle days 5-10 were being a BRCA1 mutation carrier (p=0.002), lack of current OC use (p=0.003), and being nulliparous (p=0.01), adjusted for age and menstrual cycle day when the samples were obtained. This association was seen both in non-OC users and current OC users but was only significant in the former group (p=0.005). Because of multiple analyses it is possible that our finding is a result of a Type 1 statistical error. After a permutation test the new adjusted p value in non-OC users was 0.05. FSH and E2 were similar in non-carriers, BRCA1 mutation carriers and women from non-BRCA1/2 families. We found significantly elevated LH levels in the follicular phase among young healthy BRCA1 mutation carriers compared with non-carriers from BRCA1 families. This is a small study and confirmatory studies are warranted to establish whether elevated LH levels are part of the BRCA1 phenotype and may be manipulated in order to reduce cancer risks in BRCA1 mutation carriers.
authors.affiliation: Department of Oncology, Institute for Clinical Sciences, Lund University, Lund, Sweden. Helena.Jernstrom@med.lu.se
authors.forename: Helena
authors.initials: H
authors.lastname: Jernström
authors.forename: Ke
authors.initials: K
authors.lastname: Borg
authors.forename: Håkan
authors.initials: H
authors.lastname: Olsson
mesh_terms: D001943:Breast Neoplasms / Q000097:blood* / Q000235:genetics; D005260:Female; D005498:Follicular Phase; D019398:Genes, BRCA1; D006580:Genetic Carrier Screening; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D009154:Mutation; D010051:Ovarian Neoplasms / Q000097:blood* / Q000235:genetics
chemical_list: D007986:Luteinizing Hormone